Latest Management Changes News

My Foodie Box Limited, soon to be Tarrina Resources Limited, is pivoting from meal kits to mineral exploration by acquiring promising gold and base metal projects and raising $5 million to fund exploration.

PYC Therapeutics has restructured its Board and executive team to steer the company through pivotal clinical milestones expected by the end of 2027. The changes signal a strategic push toward late-stage development of its RNA-based drug candidates.

Following its recent sale transaction, MPR Australia Limited announces significant board resignations alongside continued leadership under CEO Nathan Wise, signaling a strategic transition phase.

Tambourah Metals has announced the immediate departure of CEO and exploration manager Terry Topping, while reaffirming its strong funding position to continue advancing its gold and critical minerals projects.

Brickworks Limited shares have been suspended from the ASX following court approval of a scheme of arrangement that will see Washington H. Soul Pattison acquire the company through a subsidiary.

Metal Bank Limited has agreed to acquire Hastings Technology Metals’ Western Australian gold assets, expanding its portfolio and advancing key projects toward production.

Elanor Investors Group advances its strategic alliance with Rockworth Capital Partners through a $125 million recapitalisation and Firmus acquisition, while rejecting an unsolicited takeover offer for its commercial property fund. The group also reports FY24 results highlighting stabilisation efforts amid high gearing.

Coventry Group Ltd reported a challenging FY25 with a 1.7% revenue decline and a 40.9% drop in underlying EBITDA, culminating in a $29.6 million net loss. The company is now targeting over $20 million EBITDA in FY26 through aggressive cost reductions and operational recalibration.

Duxton Water Limited has declared its 17th consecutive dividend increase at 3.72 cents per share, fully franked, while removing the discount on its Dividend Reinvestment Plan following a major debt repayment.

Immutep Limited reported a widened loss of A$61.4 million for FY2025, driven by increased R&D and clinical trial expenses, while progressing its lead immunotherapy candidate into a pivotal Phase III lung cancer trial. The company maintains a robust cash position supporting operations through 2026.

Aurora Labs reported a 34% increase in loss after tax to $3.75 million for FY2025, alongside a 327% surge in revenue driven by defence contracts and 3D printing services. The company is progressing its micro gas turbine propulsion systems and pursuing aerospace certification to expand its market footprint.

NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.